ArticleNature2020
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06639282 (SIPO1-AD), which is not on this map. Cited by 651 papers.
0numbers the graph read from it
0cells of the map it votes in
651citing papers in PubMed
53.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease
Who cites it
651 citing papers in PubMed, 958 citations in OpenAlex.
- Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trial.Alzheimer's research & therapy · 2025Trial
- Cytokine circuits in CNS homeostasis and disease.Nature immunology · 2026Review
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Hospital-treated infection associated with Alzheimer's disease pathology: underlying mechanisms.Molecular psychiatry · 2026Review
- Targeting cytokine-driven neuroinflammation in Alzheimer's disease: mechanistic insights and pharmacological strategies.Inflammopharmacology · 2026Review
- ZBP1-mediated Treg cell dysfunction exacerbates neuroimmune dysregulation in Alzheimer's disease under metabolic stress.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Peripheral Immune Alterations and T Cell Clonal Dynamics Across the Parkinson's Disease Spectrum.medRxiv : the preprint server for health sciences · 2026Article
- Impaired regulatory T-cell-mediated immune tolerance promotes neurodegeneration in glaucoma.medRxiv : the preprint server for health sciences · 2026Article
- Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Serum Granzyme B in Parkinson's Disease: A Case-Control Study of Diagnostic Association.Journal of clinical medicine · 2026Article
- Olfactory-Cleft Biopsy in Alzheimer's Disease: An Emerging Neuroimmune Window into Preclinical Pathobiology.International journal of molecular sciences · 2026Review
- Neuroimmune interactions: from molecular mechanisms to therapeutic targets.Molecular biomedicine · 2026Review
- Clonal CD8 T cells link peripheral and intrathecal immunity in ALS4 progression: a multiomics reference for ALS.Research square · 2026Article
- Cytomegalovirus-induced T cell responses accelerate Alzheimer's disease progression in mice.Brain : a journal of neurology · 2026Article
- Priming of CD8Nature neuroscience · 2026Article
- Not every gene is special: Modelling scale controls the false discovery rate when analysing high-throughput sequencing data.PLoS computational biology · 2026Article
- T Cell Thoughts.Immunological reviews · 2026Review
- Microglia prune developing cortical blood vessels through PD-1 signaling.Nature neuroscience · 2026Article
- The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.Inflammopharmacology · 2026Review
- Review
591 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors at 7 institutions in 3 countries.
David GateDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. dgate@stanford.edu.
Naresha SaligramaDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.
Olivia LeventhalDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Andrew C YangDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Michael S UngerInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Jinte MiddeldorpDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Kelly ChenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Benoit LehallierDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Divya ChannappaDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Mark B De Los SantosDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Alisha McBrideDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
John PluvinageDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Fanny ElahiDepartment of Neurology, Memory and Aging Center, University of California at San Francisco, San Francisco, CA, USA.
Grace Kyin-Ye TamDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Yongha KimDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Michael GreiciusDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Anthony D WagnerDepartment of Psychology, Stanford University, Stanford, CA, USA.
Ludwig AignerInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
Douglas R GalaskoDepartment of Neurosciences, University of California at San Diego, La Jolla, CA, USA.
Mark M DavisDepartment of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.
Tony Wyss-CorayDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.
Stanford University · USParacelsus Medical University · ATHoward Hughes Medical Institute · USNeurosciences Institute · USUniversity Memory and Aging Center · USUniversity of California, San Diego · USUtrecht University · NL
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BRUCE L MILLER · 2002 to 2026
$67.2MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOWARD J ROSEN · 2019 to 2026
$36.9MStanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI ELIZABETH MORMINO · 2020 to 2026
$29.0MWorking Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9MMultidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4MHigh-resolution imaging of hippocampal mechanisms in age-related memory decline.R01AG048076 · NIA · STANFORD UNIVERSITY · PI WAGNER, ANTHONY D · 2014 to 2018
$1.9MMultimodal Imaging in Frontotemporal DegenerationK24AG045333 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2013 to 2023
$1.9MCirculatory Rejuvenating Factors for the BrainR01AG045034 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI WYSS-CORAY, TONY · 2013 to 2017
$1.4MA novel blood-CSF adaptive immune response in Alzheimer's diseaseR00NS112458 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GATE, DAVID · 2022 to 2024
$740kA novel blood-CSF adaptive immune response in Alzheimer's diseaseK99NS112458 · NINDS · STANFORD UNIVERSITY · PI GATE, DAVID · 2020 to 2021
$245kReversing epigenetic changes in aged microglia via young circulatory factorsF32AG055255 · NIA · STANFORD UNIVERSITY · PI GATE, DAVID · 2018 to 2019
$68kHoward Hughes Medical InstituteNIAID NIH HHS U19 AI057229NIA NIH HHS F32 AG055255NIA NIH HHS F32 AG055255-01A1NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG066515NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG045034NIA NIH HHS R01 AG045034 05NIA NIH HHS R01 AG048076NIA NIH HHS T32 AG023481NINDS NIH HHS K99 NS112458NINDS NIH HHS R00 NS112458
Abstract
Alzheimer's disease is an incurable neurodegenerative disorder in which neuroinflammation has a critical function
Indexed as
AgedAlzheimer DiseaseAmino Acid SequenceCD8-Positive T-LymphocytesCerebrospinal FluidCohort StudiesHumansImmunologic MemoryMiddle AgedReceptors, Antigen, T-CellSequence Analysis, ProteinReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06639282ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.